Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth
 
 Summary
 
 Company, the leading business intelligence provider, has released its latest research “Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth”. The report provides in-depth analysis of drivers and barriers that impact the global men’s health therapeutics market. The report analyzes the markets for men’s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, market revenue, and the annual cost of treatment (ACT) are forecast until 2017 for the key geographies, as well as the leading therapeutic segments. Furthermore, the report provides profiles of the leading companies, and analyzes the mergers and acquisitions (M&As) and licensing agreements that shape the global markets.
 
 This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts.
 
 Company finds that the men’s health therapeutics market will continue to grow only moderately. The principal reason for this stagnancy will be the first patent expiry of a top selling blockbuster, Viagra. The overall men’s health market is driven by the launch of late-stage pipeline candidates and the steady increase in the diseased and treated population. The erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) markets constitute a major portion of the men’s health market. In 2010, these markets accounted for more than 80% of the total men’s health therapeutics market. Male hypogonadism accounted for 8.6% of the total market size. The premature ejaculation market represents a small portion of the total men’s health market. The premature ejaculation market does not have any FDA approved products in the major market geographies. However, it will grow at a higher rate during the forecast period compared to the erectile dysfunction and male hypogonadism market. This is because the premature ejaculation market will see the launch of promising new drugs in the future. In 2009, the global men’s health therapeutics market was estimated to be worth $9,162m. Company forecasts the market to grow at a compound annual growth rate (CAGR) of approximately 4.1% between 2010 and 2017 to record a sales value of approximately $12,163m by 2017.
 
 The men’s health market has a moderate level of unmet needs. The current treatment options in the erectile dysfunction and male hypogonadism market are efficacious and have a manageable safety profile with the exception of some rare but serious side effects. The unmet need in the premature ejaculation market is huge. This is because the market lacks any FDA approved products for treatment of the disease in major geographies. There exists an opportunity for pharmaceutical companies to produce drugs with improved efficacy, improved patient compliance and competitive pricing in the future. The men’s health pipeline does contain few potential drugs which will help sustain market growth in the forecast period. However, the men’s health Research and Development (R&D) pipeline is not very innovative, with most of the projects in the late stage pipeline being me-too products.
 
 Scope
 
 - Annualized market data for the men’s health therapeutics market from 2002 to 2010 and forecast to 2017.
 - Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism, premature ejaculation and benign prostatic hyperplasia.
 - Analysis of the men’s health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
 - Market characterization of the men’s health therapeutics market, including market size, revenue analysis by top seven geographies, generic share, annual cost of treatment, a treatment flow algorithm and treatment usage patterns.
 - Key drivers and restraints that have a significant impact on the market.
 - Coverage of pipeline molecules in various phases of drug development.
 - Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Bayer Healthcare AG, Abbott Laboratories, Endo Pharmaceuticals Holding Inc., Johnson and Johnson, VIVUS Inc. and Auxilium Pharmaceuticals, Inc.
 - Key M&A activities and licensing agreements, that have taken place in the period 2004–2011 in the global men’s health therapeutics market.
 
 Reasons to buy
 
 - Align your product portfolio to the markets with the highest growth potential.
 - Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
 - Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
 - Develop key strategic initiatives by understanding the key focus areas of leading companies.

1.1 List of Tables 5
1.2 List of Figures 8
2 Men’s Health Therapeutics Market to 2017 - Introduction 11
2.1 Overview 11
2.2 GBI Research Report Guidance 11
3 Men’s Health Therapeutics Market to 2017 - Market Characterization 12
3.1 Overview 12
3.2 Market Forecasts 13
3.3 Global Generic/Off-label Share 14
3.4 Annual Cost of Treatment 15
3.5 Treatment Usage Patterns 16
3.5.1 Diseased Population 18
3.5.2 Treatment Seeking Population 19
3.5.3 Diagnosed Population 20
3.5.4 Treated Population 21
3.5.5 Drivers and Restraints of the Men’s Health Therapeutics Market 22
4 Men’s Health Therapeutics Market To 2017 - Geographical Landscape 24
4.1 Market Forecasts by Country 24
4.2 The US 26
4.2.1 Market Forecasts 26
4.2.2 Annual Cost of Treatment 27
4.2.3 Treatment Usage Patterns 28
4.3 Top Five Countries in Europe 30
4.3.1 Market Forecasts 30
4.3.2 Annual Cost of Treatment 32
4.3.3 Treatment Usage Patterns 33
4.4 Japan 35
4.4.1 Market Forecasts 35
4.4.2 Annual Cost of Treatment 36
4.4.3 Treatment Usage Patterns 37
5 Men’s Health Therapeutics Market to 2017 - Therapeutic Landscape 40
5.1 Global Erectile Dysfunction (ED) Therapeutics Market 40
5.1.1 Market Overview 40
5.1.2 Market Forecasts 40
5.1.3 Revenue Analysis by Country 42
5.1.4 Global Generic/Off-Label Share 44
5.1.5 Annual Cost of Treatment 45
5.1.6 Treatment Flow Algorithm 46
5.1.7 Treatment Usage Patterns 47
5.1.8 Product Analysis 49
5.1.9 Drivers and Restraints of the ED Therapeutics Market 50
5.2 Global Male Hypogonadism Therapeutics Market 51
5.2.1 Market Overview 51
5.2.2 Market Forecasts 52
5.2.3 Revenue Analysis by Country 53
5.2.4 Global Generic/Off-label Share 55
5.2.5 Annual Cost of Treatment 56
5.2.6 Treatment Flow Algorithm 57
5.2.7 Treatment Usage Patterns 58
5.2.8 Product Analysis 61
5.2.9 Drivers and Restraints of the Male Hypogonadism Therapeutics Market 63
5.3 Global Premature Ejaculation (PE) Therapeutics Market 63
5.3.1 Market Overview 63
5.3.2 Market Forecasts 64
5.3.3 Revenue by Country 65
5.3.4 Global Generic/Off-Label Share 67
5.3.5 Annual Cost of Treatment 68
5.3.6 Treatment Flow Algorithm 69
5.3.7 Treatment Usage Patterns 70
5.3.8 Product Analysis 72
5.3.9 Drivers and Restraints of the PE Therapeutics Market 73
5.4 Global Benign Prostatic Hyperplasia (BPH) Market 74
5.4.1 Overview 74
5.4.2 Market Forecasts 74
5.4.3 Revenue Analysis by Country 76
5.4.4 Generics/Off-Label Share 77
5.4.5 Annual Cost of Treatment 78
5.4.6 Treatment Flow Algorithm 79
5.4.7 Treatment Usage Patterns 80
5.4.8 Product Analysis 83
5.4.9 Drivers and Restraints of the BPH Therapeutics Market 84
6 Men’s Health Therapeutics Market to 2017 - Pipeline Analysis 85
6.1 Overview 85
6.2 Research and Development Pipeline by Indication 85
6.3 Research and Development by Phase of Development 87
6.4 Research and Development Pipeline - Erectile Dysfunction 88
6.4.1 Pipeline by Clinical Phases of Development 89
6.4.2 Profiles of Key Late-Stage Drugs in the Erectile Dysfunction Market 90
6.5 Research and Development Pipeline - Premature Ejaculation 93
6.5.1 Pipeline by Clinical Phases of Development 94
6.5.2 Profiles of Key Late-Stage Drugs in the Premature Ejaculation Market 95
6.6 Research and Development Pipeline - Male Hypogonadism 96
6.6.1 Pipeline by Clinical Phases of Development 97
6.6.2 Profiles of Key Late-Stage Drugs in the Male Hypogonadism Market 98
6.7 Research and Development Pipeline - Benign Prostatic Hyperplasia 99
6.7.1 Pipeline by Clinical Phases of Development 100
6.7.2 Profiles of Key Late-Stage Drugs in the Benign Prostatic Hyperplasia Market 102
7 Men’s Health Therapeutics Market to 2017 - Competitive Landscape 104
7.1 Overview 104
7.2 Company Profiles 104
7.2.1 Pfizer Inc. 104
7.2.2 Eli Lilly and Company 105
7.2.3 GlaxoSmithKline, Inc 106
7.2.4 Abbott Laboratories 107
7.2.5 Endo Pharmaceuticals Holding Inc. 108
7.2.6 Bayer Healthcare AG 109
7.2.7 Johnson & Johnson 110
7.2.8 VIVUS, Inc. 111
7.2.9 Auxilium Pharmaceuticals, Inc. 112
8 Men’s Health Therapeutics Market to 2017 - Strategic Consolidations 113
8.1 Overview 113
8.2 Mergers and Acquisitions 114
8.2.1 Overview 114
8.2.2 Major M&A Deals 117
8.3 Licensing Agreements 118
8.3.1 Deals by Geography 118
8.3.2 Deals by Value 119
8.3.3 Deals by Year 120
8.4 Major Licensing Agreements 121
8.5 Co-Development Deals 122
8.5.1 Major Co-Development Deals 122
9 Men’s Health Therapeutics Market to 2017 - Appendix 123
9.1 Market Definitions 123
9.2 Abbreviations 123
9.3 Research Methodology 124
9.3.1 Coverage 124
9.3.2 Secondary Research 125
9.3.3 Primary Research 125
9.3.4 Therapeutic Landscape 126
9.3.5 Epidemiology-based Forecasting 126
9.3.6 Market Size by Geography 128
9.3.7 Geographical Landscape 129
9.3.8 Pipeline Analysis 129
9.3.9 Competitive Landscape 129
9.3.10 Expert Panel Validation 129
9.4 Contact Us 129
9.5 Disclaimer 129
9.6 Sources 130

1.1 List of Tables

Table 1: Men’s Health Therapeutics Market to 2017, Global, Revenue, $m, 2002-2010 13
Table 2: Men’s Health Therapeutics Market to 2017, Global, Revenue Forecasts ,$m, 2010-2017 13
Table 3: Men’s Health Therapeutics Market to 2017, Global, Annual Cost of Treatment, $, 2002-2010 15
Table 4: Men’s Health Therapeutics Market to 2017, Global, Annual Cost of Treatment ,$, 2010-2017 15
Table 5: Men’s Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2002-2010 16
Table 6: Men’s Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2010-2017 17
Table 7: Men’s Health Therapeutics Market to 2017, Global, Revenue Analysis by Country, $m, 2002-2010 24
Table 8: Men’s Health Therapeutics Market to 2017, Global, Revenue Analysis by Country, $m, 2010-2017 25
Table 9: Men’s Health Therapeutics Market to 2017, The US, Revenue, $m, 2002-2010 26
Table 10: Men’s Health Therapeutics Market to 2017, The US, Revenue Forecasts ,$m, 2010-2017 26
Table 11: Men’s Health Therapeutics Market to 2017, The US, Annual Cost of Treatment, $, 2002-2010 27
Table 12: Men’s Health Therapeutics Market to 2017, The US, Annual Cost of Treatment, $, 2010-2017 27
Table 13: Men’s Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2002-2010 28
Table 14: Men’s Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2010-2017 29
Table 15: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue, $m, 2002-2010 30
Table 16: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Forecasts, $m, 2010-2017 30
Table 17: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2002-2010 31
Table 18: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2010-2017 31
Table 19: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2002-2010 32
Table 20: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2010-2017 32
Table 21: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2002-2010 33
Table 22: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2010-2017 34
Table 23: Men’s Health Therapeutics Market to 2017, Japan, Revenue, $m, 2002-2010 35
Table 24: Men’s Health Therapeutics Market to 2017, Japan, Revenue Forecasts, $m, 2010-2017 35
Table 25: Men’s Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2002-2010 36
Table 26: Men’s Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2010-2017 36
Table 27: Men’s Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2002-2010 37
Table 28: Men’s Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2010-2017 38
Table 29: Erectile Dysfunction Therapeutics Market, Global, Revenue, $m, 2002-2010 41
Table 30: Erectile Dysfunction Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 41
Table 31: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010 42
Table 32: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017 43
Table 33: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010 45
Table 34: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017 45
Table 35: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2010 47
Table 36: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2010-2017 48
Table 37: Male Hypogonadism Therapeutics Market, Global, Revenue, $m, 2002-2010 52
Table 38: Male Hypogonadism Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 53
Table 39: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010 54
Table 40: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017 54
Table 41: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010 56
Table 42: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017 56
Table 43: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2010 58
Table 44: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2010-2017 59
Table 45: Premature Ejaculation Therapeutics Market, Global, Revenue, $m, 2002-2010 64
Table 46: Premature Ejaculation Therapeutics Market, Global, Revenue Forecasts, $m, 2010-2017 65
Table 47: Premature Ejaculation Therapeutics Market, Global, Revenue by Country ,$m, 2002-2010 66
Table 48: Premature Ejaculation Therapeutics Market, Global, Revenue by Country, $m, 2010-2017 66
Table 49: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment , $, 2002-2010 68
Table 50: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017 68
Table 51: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2010 70
Table 52: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, million, 2010-2017 71
Table 53: BPH Therapeutics Market, Global, Revenue, $bn, 2002-2010 75
Table 54: BPH Therapeutics Market, Global, Revenue Forecasts, $bn, 2010-2017 75
Table 55: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2010 76
Table 56: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2010-2017 77
Table 57: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2010 78
Table 58: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2010-2017 78
Table 59: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 81
Table 60: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 81
Table 61: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Indication, (%), 2011 86
Table 62: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase, (%), 2011 87
Table 63: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Erectile Dysfunction Market, (%), 2011 88
Table 64: Erectile Dysfunction Therapeutics Market, Global, Discovery Pipeline Molecules, 2011 89
Table 65: Erectile Dysfunction Therapeutics Market, Global, Preclinical/IND Filed Pipeline Molecules, 2011 89
Table 66: Erectile Dysfunction Therapeutics Market, Global, Phase I Pipeline Molecules, 2011 89
Table 67: Erectile Dysfunction Therapeutics Market, Global, Phase II Pipeline Molecules, 2011 89
Table 68: Erectile Dysfunction Therapeutics Market, Global, Phase III Pipeline Molecules, 2011 90
Table 69: Erectile Dysfunction Therapeutics Market, Global, NDA Filed Molecules, 2011 90
Table 70: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in the Premature Ejaculation Market, (%), 2011 93
Table 71: Premature Ejaculation Therapeutics Market. Global, Discovery Pipeline Molecules, 2011 94
Table 72: Premature Ejaculation Therapeutics Market. Global, Preclinical Pipeline Molecules, 2011 94
Table 73: Premature Ejaculation Therapeutics Market. Global, Phase I Pipeline Molecules, 2011 94
Table 74: Premature Ejaculation Therapeutics Market. Global, Phase II Pipeline Molecules, 2011 94
Table 75: Premature Ejaculation Therapeutics Market. Global, Phase III Pipeline Molecules, 2011 95
Table 76: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Male Hypogonadism, (%), 2011 96
Table 77: Male Hypogonadism Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 97
Table 78: Male Hypogonadism Therapeutics Market, Global, Phase I Pipeline Molecules, 2011 97
Table 79: Male Hypogonadism Therapeutics Market, Global, Phase II Pipeline Molecules, 2011 97
Table 80: Male Hypogonadism Therapeutics Market, Global, NDA Filed Pipeline Molecules, 2011 98
Table 81: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Benign Prostatic Hyperplasia, (%), 2011 99
Table 82: Benign Prostatic Hyperplasia Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 100
Table 83: Benign Prostatic Hyperplasia Market, Global, Phase I Pipeline Molecules, 2011 100
Table 84: Benign Prostatic Hyperplasia Market, Global, Phase II Pipeline Molecules, 2011 101
Table 85: Benign Prostatic Hyperplasia Market, Global, Phase III Pipeline Molecules, 2011 101
Table 86: Benign Prostatic Hyperplasia Market, Global, NDA Filed Pipeline Molecules, 2011 102
Table 87: Men’s Health Therapeutics Market to 2017, Eli Lilly and Company, Men’s Health Pipeline, 2010 105
Table 88: Men’s Health Therapeutics Market to 2017, GlaxoSmithKline, Inc., Men’s Health Pipeline, 2010 106
Table 89: Men’s Health Therapeutics Market to 2017, Abbott Laboratories, Men’s Health Pipeline, 2010 107
Table 90: Men’s Health Therapeutics Market to 2017, Endo Pharmaceuticals Holding Inc, Men’s Health Pipeline, 2010 108
Table 91: Men’s Health Therapeutics Market to 2017, Bayer Healthcare AG, Men’s Health Pipeline, 2010 109
Table 92: Men’s Health Therapeutics Market to 2017, VIVUS Inc., Men’s Health Pipeline, 2010 111
Table 93: Men’s Health Therapeutics Market to 2017, Global, Deals by Type, 2004-2011 113
Table 94: Men’s Health Therapeutics Market to 2017, Global, M&A Deals by Value, (%), 2004-2011 114
Table 95: Men’s Health Therapeutics Market to 2017, Global, M&A Deals by Geography, (%), 2004- 2011 115
Table 96: Men’s Health Therapeutics Market to 2017, Global, Number of M&A Deals by Year, 2004-2011 116
Table 97: Men’s Health Therapeutics Market to 2017, Global, Major M&A Deals, 2007-2011 117
Table 98: Men’s Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Geography (%), 2004-2011 118
Table 99: Men’s Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Value, ($m), (%), 2004-2011 119
Table 100: Men’s Health Therapeutics Market to 2017, Global, Number of Licensing Deals by Year, 2004-2011 120
Table 101: Men’ Health Therapeutics Market to 2017, Major Licensing Agreements, 2009-2010 121
Table 102: Men’s Health Therapeutics Market to 2017, Global, Major Co-Development Deals, 2004-2006 122

1.2 List of Figures

Figure 1: Men’s Health Therapeutics Market to 2017, Global, Revenue Forecasts ,$m, 2002-2017 13
Figure 2: Men’s Health Therapeutics Market to 2017, Global, Generic/Off-label Share, %, 2010, 2017 14
Figure 3: Men’s Health Therapeutics Market to 2017, Global, Annual Cost of Treatment, $, 2002-2017 15
Figure 4: Men’s Health Therapeutics Market to 2017, Global, Treatment Usage Patterns, million, 2002-2017 16
Figure 5: Men’s Health Therapeutics Market to 2017, Global, Diseased Population, million, 2002-2017 18
Figure 6: Men’s Health Therapeutics Market to 2017, Global, Treatment Seeking Population, million, 2002-2017 19
Figure 7: Men’s Health Therapeutics Market to 2017, Global, Diagnosed Population, million, 2002-2017 20
Figure 8: Men’s Health Therapeutics Market to 2017, Global, Treated Population, million, 2002-2017 21
Figure 9: Men’s Health Therapeutics Market to 2017, Global, Market Drivers and Restraints 22
Figure 10: Men’s Health Market to 2017, Revenue Analysis by Country, $m, 2002-2017 24
Figure 11: Men’s Health Therapeutics Market to 2017, The US, Revenue Forecasts ,$m, 2002-2017 26
Figure 12: Men’s Health Therapeutics Market to 2017, The US, Annual Cost of Treatment ,$, 2002-2017 27
Figure 13: Men’s Health Therapeutics Market to 2017, The US, Treatment Usage Patterns, million, 2002-2017 28
Figure 14: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Forecasts, $m, 2002-2017 30
Figure 15: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Revenue Analysis by Country, $m, 2002-2017 31
Figure 16: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment, $, 2002-2017 32
Figure 17: Men’s Health Therapeutics Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns, million, 2002-2017 33
Figure 18: Men’s Health Therapeutics Market to 2017, Japan, Revenue Forecasts, $m, 2002-2017 35
Figure 19: Men’s Health Therapeutics Market to 2017, Japan, Annual Cost of Treatment, $, 2002-2017 36
Figure 20: Men’s Health Therapeutics Market to 2017, Japan, Treatment Usage Patterns, million, 2002-2017 37
Figure 21: Erectile Dysfunction Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 41
Figure 22: Erectile Dysfunction Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017 42
Figure 23: Erectile Dysfunction Therapeutics Market, Global Generic/Off-Label Share, (%), 2010, 2017 44
Figure 24: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017 45
Figure 25: Erectile Dysfunction Therapeutics Market, Global, Treatment Flow Algorithm for Erectile Dysfunction, 2011 46
Figure 26: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, million, 2002-2017 47
Figure 27: Male Hypogonadism Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 52
Figure 28: Male Hypogonadism Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017 53
Figure 29: Male Hypogonadism Therapeutics Market, Global, Global Generic/Off-Label Share, $m, 2010, 2017 55
Figure 30: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017 56
Figure 31: Male Hypogonadism Therapeutics Market, Global, Treatment Flow Algorithm for Male Hypogonadism, 2011 57
Figure 32: Male Hypogonadism Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017 58
Figure 33: Male Hypogonadism Therapeutics Market to 2017, Global, Prescription Share Analysis, (%), 2010 61
Figure 34: Premature Ejaculation Therapeutics Market, Global, Revenue Forecasts, $m, 2002-2017 64
Figure 35: Premature Ejaculation Therapeutics Market, Global, Revenue by Country, $m, 2002-2017 65
Figure 36: Premature Ejaculation Therapeutics Market, Global Generic Share, $m, 2010- 2017 67
Figure 37: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017 68
Figure 38: Premature Ejaculation Therapeutics Market, Global, Treatment Flow Algorithm for Premature Ejaculation 69
Figure 39: Premature Ejaculation Therapeutics Market, Global, Treatment Usage Patterns, (‘000), 2002-2017 70
Figure 40: BPH Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 75
Figure 41: BPH Therapeutics Market, Global, Revenue Analysis by Country, $m, 2002-2017 76
Figure 42: BPH Therapeutics Market, Global Generics/Off-Label Share, %, 2010, 2017 77
Figure 43: BPH Therapeutics Market, Global, Annual Cost of Treatment, $, 2002-2017 78
Figure 44: BPH Therapeutics Market, Global, Treatment Flow Algorithm for BPH, 2011 79
Figure 45: BPH Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 80
Figure 46: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Indication, (%), 2011 85
Figure 47: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase, (%), 2011 87
Figure 48: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Erectile Dysfunction Market, (%), 2011 88
Figure 49: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in the Premature Ejaculation Market, (%), 2011 93
Figure 50: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Male Hypogonadism, (%), 2011 96
Figure 51: Men’s Health Therapeutics Market to 2017, Global, R&D Pipeline by Phase in Benign Prostatic Hyperplasia, (%), 2011 99
Figure 52: Men’s Health Therapeutics Market to 2017, Pfizer Inc., SWOT Analysis, 2011 104
Figure 53: Men’s Health Therapeutics Market to 2017, Eli Lilly and Company, SWOT Analysis, 2010 105
Figure 54: Men’s Health Therapeutics Market to 2017, GlaxoSmithKline, Inc, SWOT Analysis, 2010 106
Figure 55: Men’s Health Therapeutics Market to 2017, Abbott Laboratories, SWOT Analysis, 2010 107
Figure 56: Men’s Health Therapeutics Market to 2017, Endo Pharmaceuticals Holding Inc, SWOT Analysis, 2010 108
Figure 57: Men’s Health Therapeutics Market to 2017, Bayer Healthcare AG, SWOT Analysis, 2010 109
Figure 58: Men’s Health Therapeutics Market to 2017, Johnson & Johnson, SWOT Analysis, 2010 110
Figure 59: Men’s Health Therapeutics Market to 2017, VIVUS Inc., SWOT Analysis, 2010 111
Figure 60: Men’s Health Therapeutics Market to 2017, Auxilium Pharmaceuticals, Inc, SWOT Analysis, 2010 112
Figure 61: Men’s Health Therapeutics Market to 2017, Global, Deals by Type, (%), 2004-2011 113
Figure 62: Men’s Health Therapeutics Market to 2017, Global, M&A Deals by Value, (%), 2004-2011 114
Figure 63: Men’s Health Therapeutics Market to 2017, Global, M&A Deals by Geography, (%), 2004- 2011 115
Figure 64: Men’s Health Therapeutics Market to 2017, Global, Number of M&A Deals by Year, 2004-2011 116
Figure 65: Men’s Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Geography, (%), 2004-2011 118
Figure 66: Men’s Health Therapeutics Market to 2017, Global, Major Licensing Agreements By Value, $m, (%), 2004-2011 119
Figure 67: Men’s Health Therapeutics Market to 2017, Global, Number of Licensing Deals by Year, 2004-2011 120
Figure 68: GBI Research Market Forecasting Model 128

Companies Menstion

Pfizer Inc.
Eli Lilly and Company
GlaxoSmithKline, Inc
Abbott Laboratories
Endo Pharmaceuticals Holding Inc.
Bayer Healthcare AG
Johnson & Johnson
VIVUS, Inc.
Auxilium Pharmaceuticals, Inc.